BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)
China flag China · Delayed Price · Currency is CNY
27.03
-0.86 (-3.08%)
At close: Nov 17, 2026

SHA:688166 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
1,230961.06765.35998.051,180336.84
Trading Asset Securities
119.03--50.6250.120.76
Cash & Short-Term Investments
1,349961.06765.351,0491,230337.6
Cash Growth
122.51%25.57%-27.02%-14.78%264.48%-35.02%
Accounts Receivable
318.29330.02339.5308.88307.47373.85
Other Receivables
3.339.136.6619.9118.783.75
Receivables
321.62339.14346.17328.79326.25377.59
Inventory
338.51364.25364.61344.63280.35200.06
Prepaid Expenses
---3.655.834.48
Other Current Assets
141.12124.04164.1411495.3973.27
Total Current Assets
2,1501,7891,6401,8401,938993.01
Property, Plant & Equipment
2,7982,7522,7052,4892,0761,378
Long-Term Investments
516.58671.08437.06425.86399.33348.28
Goodwill
--3.127.57.57.5
Other Intangible Assets
76.6579.5389.4893.6681.6480.84
Long-Term Accounts Receivable
-4.12.1---
Long-Term Deferred Tax Assets
128.894.6862.242.2823.9419.86
Long-Term Deferred Charges
420.97339.1957.4930.1826.8725.83
Other Long-Term Assets
431.395.42156.03104.09107.73115.86
Total Assets
6,5235,8255,1535,0324,6612,970

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
147.22185.89266228.18252.19211.89
Accrued Expenses
15.3282.9772.0172.3169.0461.72
Short-Term Debt
79.54110.11115.26156.87124.38257.05
Current Portion of Long-Term Debt
802.87775.1516.96397.93313.8716.58
Current Portion of Leases
-8.8313.6916.11.349.87
Current Income Taxes Payable
14.3210.6116.6814.0414.973.69
Current Unearned Revenue
43.325.5628.022429.4920.33
Other Current Liabilities
30.3481.2323.7612.816.261.93
Total Current Liabilities
1,1331,2801,052922.25811.52583.07
Long-Term Debt
1,6431,4901,5801,6151,576618.69
Long-Term Leases
19.5310.2110.2121.016.010.22
Long-Term Unearned Revenue
182.73167.5884.7126.252626
Other Long-Term Liabilities
91.9730.3-29.82--
Total Liabilities
3,0702,9792,7272,6142,4201,228

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
435.79423.1422.47422.47422.47410
Additional Paid-In Capital
1,6151,076982.361,0571,008738.94
Retained Earnings
1,1811,0661,046897.66743.35555.05
Treasury Stock
-20.05-20.05-10.01---
Comprehensive Income & Other
-120.01-24.21-57.82-8.6417.77-25.8
Total Common Equity
3,0922,5212,3832,3692,1921,678
Minority Interest
360.29325.0142.7348.9750.0463.45
Shareholders' Equity
3,4522,8462,4262,4182,2421,742
Total Liabilities & Equity
6,5235,8255,1535,0324,6612,970

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
2,5452,3952,2362,2072,022902.42
Net Cash (Debt)
-1,196-1,433-1,470-1,158-791.15-564.82
Net Cash Growth
------
Net Cash Per Share
-2.82-3.42-3.50-2.75-1.91-1.39
Filing Date Shares Outstanding
435.23422.54422.11422.1422.47410
Total Common Shares Outstanding
435.23422.54422.11422.47422.47410
Working Capital
1,017508.2587.89917.491,127409.94
Book Value Per Share
7.105.975.655.615.194.09
Tangible Book Value
3,0162,4422,2912,2672,1031,590
Tangible Book Value Per Share
6.935.785.435.374.983.88
Buildings
-745.28728.65261.26273.4104.72
Machinery
-1,2711,122704.8318.41287.37
Construction In Progress
-1,1871,1671,7361,6661,131